gefitinib has been researched along with pi103 in 11 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (pi103) | Trials (pi103) | Recent Studies (post-2010) (pi103) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 181 | 0 | 139 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Aizenstein, B; Apsel, B; Blair, JA; Feldman, ME; Gonzalez, B; Hoffman, R; Knight, ZA; Nazif, TM; Shokat, KM; Williams, RL | 1 |
| Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB | 1 |
| Russu, WA; Shallal, HM | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Li, D; Shen, QJ; Wang, F; Xing, WH; Xu, J; Zhang, LN; Zhang, XH; Zhuo, RJ; Zou, ZQ | 1 |
| Dive, C; Harrison, LR; Mironov, A; Moreira-Leite, FF; Roberts, RA | 1 |
| Donev, IS; Li, Q; Matsumoto, K; Nishioka, Y; Sone, S; Takeuchi, S; Wang, W; Yamada, T; Yamori, T; Yano, S | 1 |
| Bae, I; Hong, W; Kang, HJ; Kim, HJ; Seong, YS; Wang, A; Yi, YW; Zhao, W | 1 |
11 other study(ies) available for gefitinib and pi103
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Blotting, Western; Catalytic Domain; Cell Proliferation; Cells, Cultured; Crystallography, X-Ray; Drug Delivery Systems; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Sequence Data; Molecular Structure; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Protein Subunits; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Sequence Alignment; Signal Transduction; TOR Serine-Threonine Kinases | 2008 |
Navigating the kinome.
Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology | 2011 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Furans; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrimidines; Quinazolines; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2009 |
Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Furans; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Pyrimidines; Quinazolines; TOR Serine-Threonine Kinases | 2010 |
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Furans; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspases; Cell Death; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Furans; Gefitinib; Humans; Inhibitory Concentration 50; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Quinazolines; Signal Transduction | 2013 |